NAD+ (nicotinamide adenine dinucleotide) is a redox coenzyme found in every living cell that shuttles electrons through energy metabolism and also serves as the fuel consumed by sirtuins and PARP DNA-repair enzymes. It is central to longevity research because cellular NAD+ levels fall with age, and that decline is tied to mitochondrial function, DNA-repair signaling, and metabolism. Most evidence is preclinical or early-stage human, and these are research compounds, not products for human consumption.
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every living cell that carries electrons through the reactions your cells use to turn food into energy. It also does a second job that put it at the center of aging science: it's the raw material that sirtuins and PARP enzymes consume when they run DNA-repair and metabolic-signaling programs. Cellular NAD+ drops as animals and people get older, and that decline is what makes it one of the most-studied molecules in longevity research.
What NAD+ actually is
At its simplest, NAD+ is an electron shuttle. It exists in two forms that cycle back and forth: the oxidized form (NAD+) picks up electrons to become the reduced form (NADH), then hands them off and returns to NAD+. That NAD+/NADH cycle runs glycolysis, the citric acid cycle, and oxidative phosphorylation - the core machinery that produces ATP. Without enough of it, energy metabolism slows down at a very basic level.
The part that drives the research interest is separate from the electron-carrier role. NAD+ is also a substrate that gets used up, not just recycled. Three families of enzymes cleave the molecule:
- Sirtuins - NAD+-dependent deacylases tied to metabolic regulation, stress response, and mitochondrial signaling. Every reaction they run consumes an NAD+ molecule.
- PARPs - poly(ADP-ribose) polymerases that fire during DNA damage repair, drawing heavily on the NAD+ pool when the genome is under stress.
- CD38 and related NADases - enzymes that break down NAD+ and appear to rise with age, which is one proposed reason the pool shrinks over time.
So NAD+ sits at an unusual intersection: it's both a recyclable cofactor for making energy and a consumable currency for repair and signaling. When demand from PARPs and CD38 goes up, less is available for sirtuins, and vice versa. That competition is a large part of why the molecule is interesting to study.
Why NAD+ is central to longevity research
The observation that started it: tissue NAD+ concentrations decline with age across multiple model organisms and, in more limited human data, in several tissues. Researchers connect that decline to three overlapping threads.
- Mitochondrial function. NAD+ is required to keep the electron transport chain running. Lower NAD+ is associated in animal models with reduced mitochondrial output and the kind of energy deficits seen in aged tissue.
- DNA-repair signaling. As DNA damage accumulates with age, PARP activity rises and consumes more NAD+, which is one proposed mechanism for how genomic stress and NAD+ depletion feed each other.
- Metabolism and sirtuin activity. Because sirtuins need NAD+ to work, falling NAD+ is hypothesized to blunt sirtuin-driven metabolic and stress-resistance programs.
Restoring NAD+ in aged animals has produced encouraging effects on mitochondrial and metabolic markers in a number of studies. The honest caveat: most of this is animal-model and mechanistic work, and translating "raises NAD+" into "extends healthy lifespan in humans" is exactly the gap current research is trying to close.
Direct NAD+ vs precursors: the real debate
You can't just add NAD+ to a cell and expect it to walk in. NAD+ is a large, charged molecule, which makes it poorly suited to crossing cell membranes and to surviving intact through digestion. That single fact shapes most of the research strategy.
Most work therefore uses precursors - smaller building blocks the body converts into NAD+ through defined salvage pathways:
- NMN (nicotinamide mononucleotide) - the last precursor before NAD+ itself; cells convert it in essentially one enzymatic step.
- NR (nicotinamide riboside) - one step further back; taken up by specific transporters and phosphorylated into NMN, then NAD+.
- Niacin / nicotinic acid and nicotinamide - the classic vitamin B3 forms that feed NAD+ synthesis through separate routes.
In practice, precursors are better characterized for raising circulating NAD+ orally than direct NAD+ is, largely because they're small enough to absorb and to use cell-specific transporters. Direct NAD+ research exists, but it wrestles with the absorption and stability problems that come with a big charged molecule, including the likelihood that some administered NAD+ is broken down into those same precursors before it's used. None of this is settled, and it's an active research question rather than a solved one.
Comparison table
| Compound | What it is | Research angle | Delivery note |
|---|---|---|---|
| NAD+ (direct) | The intact coenzyme itself | Whether supplying the finished molecule raises usable intracellular NAD+ | Large, charged; poor oral absorption and membrane crossing; non-oral routes studied to bypass the gut |
| NMN | Immediate NAD+ precursor | One of the better-studied precursors for raising circulating NAD+; one step to NAD+ | Absorbs and uses specific transporters; much of the precursor human data sits here or with NR |
| NR | Precursor one step behind NMN | Studied alongside NMN for lifting circulating NAD+ in early human work | Well-characterized oral uptake; converted to NMN then NAD+ |
Delivery routes studied for direct NAD+
Because oral direct NAD+ runs into the gut, research on the intact molecule leans on routes that skip or reduce first-pass breakdown. The rationale for each is worth understanding generally - none of the below is a dosing instruction.
- Intravenous (IV). Puts NAD+ directly into circulation, sidestepping digestion entirely. It's the route most associated with rapid changes in circulating NAD+, but it's invasive and clinical in nature, which limits its practicality as a research model.
- Subcutaneous. Aims for slower systemic entry than IV while still avoiding the gut. The trade-off is uncertainty around how much intact NAD+ actually reaches tissues versus being converted locally.
- Intranasal / atomized. The bioavailability rationale is that the nasal mucosa is thin, well-vascularized, and skips first-pass gut and liver metabolism, the same logic behind nasal nootropics and peptide nasal sprays. The challenge is real: a large charged molecule still has to cross mucosal tissue efficiently, and how much intact NAD+ makes it through is exactly the kind of thing atomized-solution research is trying to measure.
The through-line across all three: they exist to work around the absorption problem, and each trades one difficulty for another. For handling concepts on solution-form compounds generally, the reconstitution guide and storage guide cover lab-handling basics - reconstitution and storage are bench procedures, not human-use instructions.
Where BHG Labs fits
BHG Labs is an independent third-party research-compound vendor that BodyHackGuide features as an affiliate ("BHG" here does not mean BodyHackGuide). It's expanding its atomized (nasal) research-solution line, and an NAD+ atomized solution is being added to that lineup. As of now that specific NAD+ product is coming soon and not yet purchasable, so there's nothing to buy today - the BHG Labs vendor profile is simply where that atomized research line lives. For the compound itself, the NAD+ compound page tracks what it is and how it's studied.
*Independent vendor; BodyHackGuide may earn a commission. Reader discount code is REDDIT (10% off) when products are available.*
BHG Labs is one reputable, COA-per-lot option, not the only one, and not a reason to skip your own diligence. Whatever vendor you evaluate, confirm a certificate of analysis for the specific lot. Our how to read a COA guide walks through purity and identity checks, and the vendor scorecard compares sourcing practices across sellers.
Frequently asked
Weekly drops, weekly research
New guides, price-drop alerts, and reader-submitted protocols. One email a week. Unsubscribe anytime.
No spam. Unsubscribe anytime.
Discussion
Sign in to join the discussion
No comments yet โ be the first to share your thoughts!